Tennessee 2025-2026 Regular Session

Tennessee Senate Bill SB0436 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2		-	HOUSE BILL 1198
3		-	By Kumar
	2	+	<BillNo> <Sponsor>
4	3
5	4		SENATE BILL 436
6	5		By Reeves
7	6
8	7
9	8		SB0436
10	9		001713
11	10		- 1 -
12	11
13	12		AN ACT to amend Tennessee Code Annotated, Title 4;
14	13		Title 53; Title 56; Title 68 and Title 71, relative to
15	14		biosimilar medicine.
16	15
17	16		WHEREAS, the legislature finds that increasing access to biosimilar medicines has the
18	17		potential to significantly reduce prescription drug costs; and
19	18		WHEREAS, biosimilar medicines are approved according to the same federal food and
20	19		drug administration (FDA) standards of pharmaceutical quality, safety, and efficacy as the FDA's
21	20		reference medicines; and
22	21		WHEREAS, it is the intent of the legislature to eliminate barriers impeding access to
23	22		biosimilar medicines and the savings biosimilar medicines can provide; now, therefore,
24	23		BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:
25	24		SECTION 1. Tennessee Code Annotated, Section 4-3-1013(e), is amended by adding
26	25		the language "or biosimilars" at the end of the subsection.
27	26		SECTION 2. Tennessee Code Annotated, Section 56-7-3502(f)(1), is amended by
28	27		deleting the subdivision and substituting:
29	28		(1) A health carrier, health benefit plan, or utilization review organization from
30	29		requiring a patient to try an AB-rated generic equivalent product, interchangeable
31	30		biological product, or biosimilar product prior to providing coverage for the equivalent
32	31		branded prescription drug;
33	32		SECTION 3. Tennessee Code Annotated, Section 71-5-198(c), is amended by adding
34	33		the language "or biosimilars" at the end of the subsection.
35	34		SECTION 4. Tennessee Code Annotated, Section 71-5-2404(a), is amended by
36	35		deleting the language "including, but not limited to, efficacy, the use of generic drugs and
37	36
38	37
39	38		- 2 - 001713
40	39
41	40		therapeutic equivalent drugs, and cost information related to each drug" and substituting
42	41		"including efficacy; the use of generic drugs, biosimilars, and therapeutic equivalent drugs; and
43	42		cost information related to each drug".
44	43		SECTION 5. This act takes effect upon becoming a law, the public welfare requiring it.